


Cáncer colorrectal avanzado


Nuevas estrategias de tratamiento

BREAKWATER


1L CCRm BRAF V600E mutado

<u>Inclusion criteria</u>
<ul style="list-style-type: none"> • Age ≥ 16 years (or ≥ 18 years based on country) • No prior systemic treatment for metastatic disease • Measurable disease (RECIST 1.1) • BRAF V600E-mutant mCRC by local or central laboratory testing • ECOG PS 0 or 1 • Adequate bone marrow, hepatic, and renal function
<u>Exclusion criteria</u>
<ul style="list-style-type: none"> • Prior BRAF or EGFR inhibitors • Symptomatic brain metastases • MSI-H/dMMR tumors (unless patients were ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition) • Presence of a RAS mutation





SLP



SG

Seguridad

Patients, n (%)	EC n=153	EC + mFOLFOX6 n=232	SOC n=229
Duration of treatment, median (range), weeks	27.0 (2.0-153.6)	49.8 (1.3-161.9)	25.9 (2.0-150.0)
All causality			
TEAE	149 (97.4)	232 (100)	227 (99.1)
Grade 3 or 4 TEAE	65 (42.5)	189 (81.5)	153 (66.8)
Grade 5 TEAE	4 (2.6)	10 (4.3)	10 (4.4)
Serious TEAE	46 (30.1)	107 (46.1)	89 (38.9)
TEAE leading to permanent discontinuation of any study treatment	20 (13.1)	62 (26.7)	40 (17.5)
TEAE leading to dose reduction of any study treatment	16 (10.5)	152 (65.5)	124 (54.1)
TEAE leading to dose interruption of any study treatment	63 (41.2)	212 (91.4)	168 (73.4)
Treatment-related			
AE related to any drug	136 (88.9)	232 (100)	217 (94.8)
Grade 3 or 4 TRAE	24 (15.7)	177 (76.3)	134 (58.5)
Grade 5 TRAE	0	0	1 (0.4) ^a
Serious AE related to any drug	10 (6.5)	45 (19.4)	50 (21.8)

Limitaciones

- Heterogeneidad del tratamiento estándar (FOLFOX/FOLFOXIRI/CAPOX +/- Bevacizumab)
- Exclusión de MSI-H → EECC SEAMARK

Conclusión

Encorafenib + cetuximab + FOLFOX se debería considerar el estándar de tratamiento en 1L en pacientes con CCRm y mutación BRAF V600E

